Solid Biosciences

Solid’s mandate is to improve the lives of patients living with devastating neuromuscular and cardiac diseases. #TogetherWeAreSolid

[Solid Biosciences @Solid_Bio]

Solid is heading to the New Directions Conference next week!

We’re excited to share insights across Duchenne muscular dystrophy, Friedreich’s ataxia and our next-generation muscle-tropic capsid, POLARIS-101™.

Be sure to connect with our team and tune into a featured presentation from our Head of Discovery and Translational Development, Nicolas Christoforou, Ph.D.

#NewDirections #GeneticMedicine #Duchenne #FriedreichsAtaxia #MuscleBiology #SolidInside

[Solid Biosciences @Solid_Bio]

We’re excited to partner with NanoMosaic through this co-marketing agreement to help advance the next generation of gene therapies.

At Solid, we believe that unlocking the full potential of AAV requires not only innovative, precision capsid design, like our POLARIS-101™ next-generation platform, but also the ability to deeply understand and characterize what’s being delivered. By collaborating with NanoMosaic and their Tessie™ platform, we’re helping enable a more complete picture of AAV payloads – measuring capsid and transgene together and clearly distinguishing full, partial and empty particles.

This collaboration reflects our commitment to advancing the broader gene therapy ecosystem through the development of next-generation technologies. We’re proud to work with NanoMosaic to expand access to solutions that can help usher in the next wave of precision genetic medicines.

Read the full release: https://t.co/IqZcxyQSlh

#GeneTherapy #AAV #Biotech #GeneticMedicine #AdvancedManufacturing #Innovation #SolidInside

[Solid Biosciences @Solid_Bio]

Solid Biosciences will participate in the @Jefferies Global Healthcare Conference on June 3rd, where our President and CEO, Bo Cumbo, will take part in a fireside chat at 7:35 AM ET.

Join via a live webcast: https://t.co/8AOlJPlYZT

#JefferiesHealthcare #GeneticMedicine #Solidinside

[Solid Biosciences @Solid_Bio]

hank you @DDPSpain for the opportunity to have Solid’s Patrick González, PhD, Vice President and Head of Clinical Science, share insights on SGT‑003, our next-generation gene therapy candidate for DMD, during last week’s Clinical Trials session. #congresoDPPE2026 #desafioduchenne

[Duchenne Parent Project España @DPPSpain]

Comienza el bloque de Ensayos Clínicos. TERAPIA GÉNICA.
Patrick González @Solid_Bio
SGT-003 Solid’s Next-Generation Gene Therapy Candidate for DMD
#congresoDPPE2026
#desafioduchenne
#fuerzaBecker

[Solid Biosciences @Solid_Bio]

Solid Biosciences was proud to participate in the @DPPSpain's International Congress 2026, where Patrick Gonzalez, PhD, Vice President and Head of Clinical Science, presented on SGT-003, our next-generation investigational gene therapy for Duchenne muscular dystrophy.

The presentation provided an update on SGT-003, highlighting progress from both the Phase 1/2 INSPIRE DUCHENNE and the Phase 3 IMPACT DUCHENNE clinical trials. The session underscored the continued advancement of SGT-003 and its potential to deliver meaningful impact for individuals living with Duchenne.

We are grateful for the opportunity to engage with the global Duchenne community and contribute to important conversations shaping the future of gene therapy and clinical innovation.

#Duchenne #GeneTherapy #DuchenneCommunity #SGT003 #RareDisease #Biotech #HealthcareInnovation #SolidBiosciences

[Solid Biosciences @Solid_Bio]

As we come to the end of FA Awareness Month, we’re proud to stand alongside the FA community in the shared mission to cure Friedreich’s ataxia.

At Solid Biosciences, we’re advancing our novel, dual-route investigational gene therapy, SGT‑212, designed to target the neurologic cardiac and systemic manifestations of Friedreich’s ataxia.

We’re committed to working with patient advocacy groups to move science forward and bring meaningful therapies to those who need them most.

#FriedreichsAtaxia #FACommunity #GeneTherapy #RareDisease #CommunityToCureFA

[Solid Biosciences @Solid_Bio]

It was a privilege to connect with so many members of the gene and cell therapy community at #ASGCT2026.  We are continually inspired by our industry's shared commitment to advancing innovation for patients.

Thank you to everyone who attended our presentations, exchanged insights with our team, and discussed the latest clinical advancements we’re making across our pipeline.

#SolidInside #ASGCT #GeneAndCellTherapy #PrecisionGeneticMedicine #RareDisease

[Solid Biosciences @Solid_Bio]

We are excited to share that Solid Biosciences is a proud sponsor of the @CureDuchenne 2026 FUTURES National Conference in Orlando, FL, taking place May 21–24.

Our SVP of Patient Advocacy, Annie Ganot, will be presenting and we'll have an exhibit table. Please be sure to stop by to learn more about our Duchenne gene therapy program.

#CureDuchenne #2026FUTURES #WeWILLCureDuchenne

[Solid Biosciences @Solid_Bio]

In his #FierceBiotechWeek keynote, Gabriel Brooks, M.D., Solid Biosciences’ Chief Medical Officer, highlighted why delivery approaches are as critical as the therapy itself, and explored how overcoming targeting constraints can help unlock the potential of genetic medicine.

Solid’s neuromuscular development programs span two complementary precision targeting strategies: molecular lock‑and‑key capsid engineering for selective tissue engagement, and precision anatomic targeting to reach specific disease drivers.

Together, these strategies reflect a platform mindset -- designing therapeutic delivery around disease biology to expand the impact of genetic medicines.

#PrecisionTargeting #GeneTherapy #GeneticMedicine #SolidInside

[Solid Biosciences @Solid_Bio]

Be sure to tune in to @CureFA_org's informational webinar with Solid Biosciences for people living with Friedreich's ataxia and their families on May 26 at 12 PM ET.   

This community session will cover our investigational, dual-route administration gene therapy for FA, SGT-212, and our ongoing, Phase 1b FALCON clinical trial. 

Register here: https://t.co/qbpGNz4tJi

#CureFA #FriedreichsAtaxia #FACommunity #CommunityToCureFA

[Solid Biosciences @Solid_Bio]

Today, we recognize Friedreich’s Ataxia Awareness Day and the strength of the FA community. We are privileged to highlight two families living with FA, and the hope and support they draw from those around them.

At Solid Biosciences, their resilience fuels our commitment to making meaningful progress. We are advancing SGT-212, our investigational, dual-route administration gene therapy for FA, which is being evaluated in the ongoing Phase 1b FALCON clinical trial.

We are proud to stand alongside advocacy partners like Friedreich's Ataxia Research Alliance (FARA) and the @NAF_Ataxia, among others, to further support patients and families impacted by FA.

Thank you Marinda Cauley, Liam Cauley, Marcy Freed, and Greyson Freed for helping us raise awareness for FA.

#FAAwarenessDay #CureFA #FriedreichsAtaxia #FACommunity

[Solid Biosciences @Solid_Bio]

Don’t miss a free community webinar we are co-hosting with @defeatduchenne on Wednesday, May 27, at 1:00 PM ET.

We look forward to discussing SGT-003, our investigational gene therapy for #DuchenneMuscularDystrophy, and our two ongoing Duchenne clinical trials. Tune in as Annie Ganot and Patrick Gonzalez, PhD, discuss program progress and answer questions from the Duchenne community.

#GeneTherapy #DuchenneCommunity

[Defeat Duchenne Canada @defeatduchenne]

On May 27 at 1:00 PM ET, Defeat Duchenne Canada and Solid Biosciences (@Solid_Bio) are hosting a free community webinar with the latest updates on SGT-003, an investigational next-generation gene therapy for Duchenne.

Register and bring your questions: https://t.co/wOpIEUmfWJ

[Solid Biosciences @Solid_Bio]

Solid Biosciences today announced financial results and business updates for the first quarter of 2026.

Read the full release: https://t.co/neaC36MQAd

$SLDB

[Solid Biosciences @Solid_Bio]

Solid Biosciences is pleased to announce that the first participant has been dosed in the Phase 3 IMPACT DUCHENNE trial evaluating SGT-003, our investigational gene therapy for Duchenne muscular dystrophy.

As we advance this clinical program, we recognize that milestones like this are only achieved through collaboration. Thank you to the patients, families, and investigators who are making this work possible as we strive to drive meaningful change for the #Duchenne community.

https://t.co/Sy6WpTnxI7

#GeneTherapy #DuchenneMuscularDystrophy #DuchenneCommunity

[Solid Biosciences @Solid_Bio]

Solid Biosciences’ Chief Medical Officer, Gabriel Brooks, M.D., will be presenting at #FierceBiotechWeek on Wednesday, May 13, from 10:10 - 10:35 am in Boston, MA.

He will discuss a critical challenge in genetic medicine: ensuring therapies are delivered precisely where they are needed most.

Learn more about the session here: https://t.co/rPHs25CjPY

#GeneTherapy #GeneticMedicine #SolidInside

[Solid Biosciences @Solid_Bio]

In recognition of Friedreich’s Ataxia Awareness Month, we stand alongside the FA community and reaffirm our commitment to advancing research together.

To ensure our work remains rooted in real-world experiences, we recently hosted an internal panel discussion focused on the realities of living with FA at our headquarters in Boston. We are incredibly grateful for the opportunity to learn directly from patients, families, and healthcare professionals. Listening to your voices is essential to help us both deepen our understanding of unmet needs and guide our work forward.

A big thank you to our panelists: @RussellLonser, Marinda Cauley, and Liam Cauley

#CommunityToCureFA #FriedreichAtaxia #RareDisease #PatientAdvocacy